前列地尔联合胰激肽原酶治疗老年人糖尿病周围神经病变的疗效观察  

Effectiveness of combined alprostadil and pancreatic kininogenas in treating gerontai diabetic peripheral neuropathy

作　　者：张玉[1] 戴红双 冯佳庆[1] 

机构地区：[1]黑龙江省大庆龙南医院内分泌科,大庆163453 [2]大庆医学高等专科学校护理系

出　　处：《中华老年医学杂志》2012年第12期1070-1072,共3页Chinese Journal of Geriatrics

摘　　要：目的观察前列地尔联合胰激肽原酶治疗老年人糖尿病周围神经病变的疗效。方法选择糖尿病周围神经病变老年患者90例随机分为3组，对照组：单纯应用甲钴胺；治疗1组：甲钴胺＋胰激肽原酶；治疗2组：甲钴胺＋前列地尔＋胰激肽原酶，疗程4周，比较治疗后各组有效率及神经传导速度的差异。结果治疗后总有效率治疗1组（80．0％）和治疗2组（100．0％）与对照组（53．3％）比较，差异有统计学意义（x2=4．80、18．26，均P〈0．05）。治疗后对照组、治疗1组和治疗2组腓总运动神经传导速度分别为（38．0±2．7）m／s、（41．9±2．9）m／s和（46．9±2．9）m／s，正中运动神经传导速度分别为（44．5±2．5）m／s、（45．9±2．3）m／s和（50．9±2．2）m／s，腓总感觉神经传导速度分别为（39．1±3．5）m／s、（42．9±3．6）m／s和（45．9±4．i）m／s，正中感觉神经传导速度分别为（43．1±3．5）m／s、（46．7±2．8）m／s和（50．6±4．1）m／s；治疗2组优于对照组（t=14．25、12．97、7．12、6．93，均P〈0．05）和治疗I组（F12．10、7．16、3．21、4．64，均P〈0．05）。结论前列地尔联合胰激肽原酶治疗老年人糖尿病周围神经病变安全、有效。Objective To observe the clinical effectiveness of alprostadil combined to pancreatic kininogenas in the treatment of gerontal diabetic peripheral neuropathy. Methods Totally 90 gerontal patients with diabetic peripheral neuropathy were randomly divided into three groups,the first group received the treatment of mecobalamin, the second group received mecobalamin plus pancreatic kininogenas,the last group received mecobalamin, alprostadil and pancreatic kininogenas （30 cases for each）. The course of treatment was 4 weeks,the nerve conduction and effective rate of 3 groups were compared after treatment. Results Compared with the first group（53.3 %）, the total effective rate was significantly improved in the second group （80.0%）and the third group（10%）（P〈0.05）. After treatment, the therapeutic effect of every group was boosted, and the second group was better than the first group,and the last group was best（P〈0.05）. Conclusions Alprostadil combined to pancreatic kininogenas is effective and safe for the treatment of elderly diabetic peripheral neuropathy.

关 键 词：前列地尔 胰激肽 糖尿病神经病变 

分 类 号：R587.2[医药卫生—内分泌]